Format

Send to

Choose Destination
Kidney Int. 2014 Nov;86(5):1057-8. doi: 10.1038/ki.2014.246.

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.

Author information

1
Division of Nephrology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
2
Division of Endocrinology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
3
Boehringer Ingelheim Canada Ltd/Ltée, Burlington, Ontario, Canada.
4
Kidney Research Centre, Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
5
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
6
Boehringer Ingelheim Norway KS, Asker, Norway.
7
Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA.
PMID:
25360497
DOI:
10.1038/ki.2014.246
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center